Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Alternative Anastrozole Target Protects Neurons in Preclinical Models of Inherited Tauopathy

ABSTRACT: Tauopathies, including Alzheimer's disease, are neurodegenerative diseases characterized by the pathological aggregation of the microtubule-associated protein Tau (MAPT). This study explores the neuroprotective properties of anastrozole, a clinical aromatase inhibitor, in both a Drosophila tauopathy model expressing human MAPTR406W and isogenic pairs of human induced pluripotent stem cell -derived cortical neurons expressing MAPT mutations. Initially identified through a Drosophila drug screen, anastrozole significantly reduced oxidative stress and Tau phosphorylation in neurons, independent of its aromatase inhibitory action. Further investigation revealed that anastrozole does not exert its protective effects through cholesterol metabolism or aromatase inhibition. Instead, screening in Drosophila identified CYP4V2 as a potential unintended target. Reducing its expression in MAPTR406W neurons recapitulated the protective effects against oxidative stress-mediated cell death. These findings position anastrozole and its off-target CYP4V2 as novel therapeutic avenues for Tauopathies and possibly in Alzheimer’s and related dementias by reducing Tau phosphorylation and oxidative stress.

ORGANISM(S): Homo sapiens

PROVIDER: GSE294023 | GEO | 2026/07/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

MAPT expression is mediated by long-range interactions with cis-regulatory elements [RNA-seq]

Project description:Tau is encoded by MAPT and abnormal aggregates of tau are a hallmark of a group of neurodegenerative diseases called tauopathies. MAPT is lowly expressed in neural progenitor cells (NPCs), but it is more highly expressed in oligodendrocytes, astrocytes, and neurons that derive from NPCs. This expression switch at differentiation suggests that MAPT expression is controlled by transcription factors and cis-regulatory elements specific to these differentiated cell types, including neurons.

2023-04-12 | GSE228115 | GEO

MAPT expression is mediated by long-range interactions with cis-regulatory elements [scMultiomics]

2023-04-12 | GSE228120 | GEO

MAPT expression is regulated by long-range interactions with cis-regulatory elements [ChIP-seq]

2023-04-12 | GSE228116 | GEO

MAPT expression is mediated by long-range interactions with cis-regulatory elements [RNA_timecourse]

2023-04-12 | GSE228119 | GEO

MAPT expression is mediated by long-range interactions with cis-regulatory elements [HiC and Capture-C]

2023-04-12 | GSE228118 | GEO

MAPT expression is mediated by long-range interactions with cis-regulatory elements [ATAC-seq]

2023-04-12 | GSE228117 | GEO

Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease

Project description:Pathological deposition of hyperphosphorylated tau in the brain closely correlates with the course of Alzheimer´s disease (AD). Tau pathology occurs first in axons of affected neurons and tau removal from axons might thus be an early intervention strategy. We report that the RNA-binding protein hnRNP R facilitates the axonal localization of the Mapt mRNA encoding tau. Mapt mRNA and tau protein were reduced in axons but not cell bodies of primary neurons cultured from hnRNP R knockout mice. Brains of 5xFAD mice deficient for hnRNP R contained less phospho-tau aggregates and amyloid-β plaques in cortex and hippocampus. Treatment of neurons with antisense oligonucleotides (MAPT-ASOs) to block hnRNP R binding to Mapt similarly reduced axonal tau levels, and intracerebroventricular injection of a MAPT-ASO ameliorated the phospho-tau and plaque load in 5xFAD mice. Lowering of tau selectively in axons thus represents an innovative therapeutic perspective for treatment of AD and other tauopathies.

2025-08-04 | PXD053387 | Pride

Promoter mutagenesis and a massively parallel reporter screen of the MAPT locus identifies cis-regulatory elements and genetic variation effects [Oligo MPRA]

Project description:Tau neurofibrillary tangles are a hallmark of several neurodegenerative diseases called tauopathies, including frontotemporal dementia and Alzheimer's Disease. Ongoing clinical trials for tauopathies seek to reduce Tau in the brain through immunotherapy, antisense oligonucleotides, and siRNA. MAPT codes for Tau, therefore understanding how the MAPT gene is regulated and the effect of genetic variation at its regulatory elements is likely to have high relevance for tauopathies. We screened a ~3 Mb region including the MAPT locus using 2 different massively parallel reporter assay (MPRA) strategies in KOLF2.1J h-NGN2 neurons and HEK293FT cells, identifying previously unannotated cis-regulatory elements (CREs). Using CRISPR interference (CRISPRi) in mixed neuron cultures, we identified a new CRE for MAPT, as well as 2 CREs for another nearby gene of interest, KANSL1. Known genetic variation from the Alzheimer's Disease sequencing project was tested in a separate MPRA at the top CREs near the MAPT gene, identifying variants with altered regulatory effects including those at previously identified CREs for MAPT. Using a saturation mutagenesis screen of a 2,000 bp region encompassing the MAPT promoter, we assessed regulatory effects of each possible single nucleotide variant in this region. We identified several neuron-specific regulatory variant effects at this region, including a high confidence binding site for the transcription factors EGR2, ZBTB14 and TCLF5 at a region of high MPRA activity and genetic conservation.

2026-03-11 | GSE324616 | GEO

Promoter mutagenesis and a massively parallel reporter screen of the MAPT locus identifies cis-regulatory elements and genetic variation effects [BAC MPRA]

2026-03-20 | GSE325585 | GEO

Promoter mutagenesis and a massively parallel reporter screen of the MAPT locus identifies cis-regulatory elements and genetic variation effects [RNA-seq]

2026-03-10 | GSE324430 | GEO